Peripheral T Cell Lymphoma Clinical Trial
Official title:
A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative
disorders. It is characterized by the presence of malignant mature T-cells or NK cells.
There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for
PTCL.
A previous phase II study conducted in US showed durable responses of pralatrexate treatment
in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior
therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm,
multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in
prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue
pralatrexate in case of CR, PR or SD.
Primary objective:
- To evaluate the objective response rate to pralatrexate in Asian PTCL patients after
prior treatment failure, as determined by independent imaging reviewer(s) using
international workshop lymphoma response criteria (IWC)
Secondary objectives:
- To determine the safety of pralatrexate in Asian PTCL patients by,
- Incidence of adverse events (AEs) and serious adverse events (SAEs) emergent from
the treatment
- To evaluate the efficacy of pralatrexate in Asian PTCL patients after prior treatment
failure by,
- Overall survival (OS), progression-free-survival (PFS), complete response (CR) and
partial response (PR) rate, and duration of CR and PR
- Treatment duration with pralatrexate in the patients without hematopoietic stem
cell transplant (HSCT) who achieve CR or PR
- Percentage of patients who undergo HSCT
- 1-year OS, 1-year PFS, and 1-year relapse rate after HSCT
- 2-year OS, 2-year PFS, and 2-year relapse rate after HSCT
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05559008 -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
|
Phase 1/Phase 2 | |
Recruiting |
NCT06083701 -
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02856997 -
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04083495 -
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05979792 -
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
|
Early Phase 1 | |
Recruiting |
NCT04984837 -
Study of Lacutamab in Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT06072131 -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
|
Phase 3 | |
Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04028440 -
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
|
Early Phase 1 | |
Not yet recruiting |
NCT05923502 -
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
|
||
Recruiting |
NCT05883449 -
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
|
Phase 2 | |
Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03586999 -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT04489264 -
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
|
||
Recruiting |
NCT06151106 -
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT02753543 -
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06089941 -
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
|